In the face of practical challenges in Indian settings such as high rates of suboptimal glycemic control, patient non-adherence to therapy, and the issue of dose-escalation with sulfonylureas, the triple drug combination of Glimepiride + Metformin + Sitagliptin offers an effective and well-tolerated therapy for patients with type 2 diabetes who are newly diagnosed and have an HbA1c >8% and those not at control with dual drug therapy.
Read more
About GemerSitaTM
Introducing for the 1st time in India - A novel combination of Glimepiride, Metformin and Sitagliptin. GemerSitaTM offers an innovative approach to control blood sugar levels effectively while minimising the risk of hypoglycaemia and weight gain. It is not just a medication; it is a step up towards a better diabetes management. Know how this triple-drug FDC offers effective glycaemic control while minimising the risk of hypoglycemia and preserving beta-cell functionality.
Play the videoSTEP UP to expert view
Continue reading to explore expert perspectives, delve into robust clinical evidence, and discover advanced treatment protocols for comprehensive diabetes management with GemerSita.TM
GemerSitaTM :Appraising the Therapeutic Rationale and Clinical Role of Triple Drug Therapy in the Management of T2DM in Indian Settings.
Read more
GemerSitaTM : Place in the management of type 2 diabetes
A practical advice on the optimal use of the fixed-dose drug combination of Glimepiride + Metformin + Sitagliptin in the Indian scenario
Read more
Clinical evidence
Explore a compendium of clinical studies and trials that underpin the efficacy and safety profile of GemerSita.TM
Read moreTreatment protocols
Find detailed guidelines on incorporating GemerSitaTM into treatment plans.
Read more
GemerSitaTM resource hub
Downloadable resources, educational materials to aid in your practice and patient interactions.